Immupharma Share Discussion Threads

[pre] 26/11/2020 09:10

The exercise price for the Options is 20p being a 54% premium to yesterdays close...looking good now...the highest existing options prices contained within the rns is 98.62p...getting interesting as we approach the FDA meeting scheduled for next week

[csmwssk12hu] 25/11/2020 15:33

Selling into strength but they can only do that for so long, 13.5 high Monday, 14 high Tuesday, 14.5 high today tomorrow?

[chesty1] 24/11/2020 13:01

Let's see what happens into close today, someone dumped!

[halfbutt] 23/11/2020 16:52

Well dont think anyone expected that end price ... :(

[parc1] 23/11/2020 12:06

Hi Llol,

Benlysta's response rate appears to have been lower but the lower placebo response gave a favourable outcome.

Lupuzor's trial had high response for the placebo and so statistical significance could not be concluded. Investigation will have now been done to establish the factors which contributed to the high response rate for the placebo.

Avion's deep research and talks with IMM have identified to an optimised trial.

Avion has a deep in-house expertise within medical and regulatory affairs and late-stage clinical development.

[chesty1] 23/11/2020 11:50

Loads of Lolly why would Avion pump money into it if they didn't think they could make it effective?

[lord loads of lolly] 23/11/2020 11:44

parc1 - Safe? Yes. Effective? Not according to the initial Phase 3 trial. Why else would the share price have tanked in April 2018?

[parc1] 23/11/2020 10:46

Worth remembering that Immupharma are funded through to end of 2023
Two US healthcare investors came forward to fund Immupharma
plus Avion's $25m is funding the phase 3 trial

Only one other product on the market to treat lupus: Benlysta
Glaxo bought Benlysta in 2012 for $3bn

On the basis of Lupuzor’s Phase IIb trial data, Lupuzor demonstrated a higher response rate and fewer side-effects compared to Benlysta’s Phase III trial. As such, Lupuzor appears to be safer and more effective and is consequently likely to see higher market uptake if approved.

Lupuzor will also be cheaper than its competitor, which is currently priced at around $30,000 annually per person.

[frrinvest] 23/11/2020 09:21

20p this week?

[halfbutt] 23/11/2020 09:14

Will we see 15p today ??

[fillipe] 23/11/2020 09:14

Wow, ask showing higher (14.65p) all the time ....15p sooner than later looks likely.

f

[csmwssk12hu] 23/11/2020 09:13

Conversion at 11p of outstanding loan, considering you only convert when share price is above conversion it makes sense to do first day after it rises above conversion, usually you would only convert aswell if you had a good idea price was about to rise, think they got timing bang on

[pre] 23/11/2020 09:10

parc121 Nov '20 - 18:30 - 36681 of 36692
0 10 0
"Although the traditional 10-month review process is designed to prevent unsafe or ineffective drugs from entering the market, FDA faces continual pressure to accelerate the regulatory review and approval of new drugs, in order to promote innovation and provide patients with serious life threatening conditions access to new therapeutic agents as quickly as possible."

"FDA have introduced four programs:

Fast Track designation
Accelerated Approval pathway
Priority Review designation
Breakthrough Therapy designation

that aim to expedite the approval process for certain agents that address 'unmet medical needs in the treatment of a serious or life-threatening condition’

Since their inception, there has been a significant increase in the number of therapeutic agents qualifying for FDA’s expedited development and review programs"

January 2018

[scrabster1] 23/11/2020 09:05

Agree Mr FX, lots of us got fleeced of 95pct of our investment.

[fillipe] 23/11/2020 08:56

ASK back up to 14p as the lowest on show, after brief dip.

f

[frrinvest] 23/11/2020 08:51

It means cash of $200K for IMM. Excellent news.

[husbod] 23/11/2020 08:31

I would have thought the fact that one of our creditors wants to convert into shares is a positive sign. It wasn't the company that was doing the diluting.

[chesty1] 23/11/2020 08:21

Started nicely blue today

Time to trend north folks!

[yes yes] 23/11/2020 07:48

Amrishbhim - can you elaborate further?

[for fx sake] 23/11/2020 07:42

"This is one company that hasn't actually let down it shareholders"Not sure those who bought in prior to the April 2018 trial results would agree.

[justtrying1] 23/11/2020 07:40

So global master fund have their hands in here no wonder didnt rise that much on friday as they will be converting and dumping all their stock any rise will be small

[amrishbhim] 23/11/2020 07:27

The reason I believe for this is because there believe there going to get the approval from FDA and needs the funds to make sure that they are ready. This is one company that hasn't actually let down it's shareholders

[for fx sake] 23/11/2020 07:12

"Conversion of convertible security"Straight in there with the dilution I see. Why don't they wait for the shares to rise first...or at least for a decision to be made?

[csmwssk12hu] 23/11/2020 00:12

Great news bring on the 4th

[parc1] 21/11/2020 18:30

"Although the traditional 10-month review process is designed to prevent unsafe or ineffective drugs from entering the market, FDA faces continual pressure to accelerate the regulatory review and approval of new drugs, in order to promote innovation and provide patients with serious life threatening conditions access to new therapeutic agents as quickly as possible."

"FDA have introduced four programs:

Fast Track designation
Accelerated Approval pathway
Priority Review designation
Breakthrough Therapy designation

that aim to expedite the approval process for certain agents that address 'unmet medical needs in the treatment of a serious or life-threatening condition’

Since their inception, there has been a significant increase in the number of therapeutic agents qualifying for FDA’s expedited development and review programs"

January 2018